EUCTR2021-005185-18-ES进行中（未招募）1 期
ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 336
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female between 18 and 75 years of age (inclusive).
- •2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel. A signed informed consent form (ICF) must be on file prior to initiating the Screening procedures.
- •3. Willing and able to complete all study requirements, restrictions, visits and procedures.
- •4. Histologic evidence of NASH based on central readings of the screening biopsy obtained no more than 6 months before Screening defined by presence of all 3 key histological features, Nonalcoholic Fatty Liver Disease Activity Score (NAS) = 4 with at least 1 point each in
- •lobular inflammation and hepatocyte ballooning
- •a. Historical biopsy may be substituted for Screening biopsy to determine eligibility if the following are met:
- •i. Historical biopsy was obtained no more than 180 ± 5 days prior to the first day of Screening.
- •ii. Hepatic tissue or slides are available for central histologic evaluation.
- •iii. No new therapeutic intervention for NASH was made 90 days prior to screening (e.g., obeticholic acid, vitamin E = 400 IU/day, pioglitazone, incretins [e.g., liraglutide, semaglutide], sodium-glucose cotransporter-2 [SGLT2] inhibitors).
- •iv. Subjects must have been metabolically stable since the biopsy (no significant weight loss = 7% of body weight, no major deterioration of glycemic control, and no introduction of new or investigational drugs for the treatment of Type 2 Diabetes
- •5. Histologic liver fibrosis stage 2 or 3 as defined by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) scoring of liver fibrosis based on central reading of the Screening biopsy (refer to criteria 4a regarding use of a historical biopsy as a substitute for the Screening biopsy).
- •6. Blood pressure up to 160/100 mmHg; potential subjects who meet other eligibility requirements, but who have out of range blood pressure measurements deemed to be not clinically significant by the investigator, may still be considered for study inclusion.
- •7. Females of reproductive potential, defined as women who have not been postmenopausal for at least 12 consecutive months (i.e., who have had menses within the preceding 12 months), or women who have not undergone surgical sterilization, specifically, hysterectomy, bilateral
- •salpingectomy, bilateral oophorectomy, hysteroscopic sterilization, and/or tubal ligation, must have a negative pregnancy test at Screening and prior to dosing at Day 1.
- •8. All participants must agree not to participate in a conception process (i.e., active attempt to become pregnant or to impregnate, sperm or egg donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant must agree to use 2 reliable methods of contraception simultaneously while receiving study treatment and for 3 months after subject has stopped taking study drug. A combination of TWO of the following methods MUST be used appropriately:
- •a. Condoms (male or female) with or without a spermicidal agent.
- •b. Diaphragm or cervical cap with spermicide.
- •c. Intrauterine device (IUD).
- •d. Hormonal-based contraception.
- •Note: Participants who are not of reproductive potential (women who have been postmenopausal for at least 12 consecutive months or have undergone hysterectomy, bilateral salpingectomy, bilateral oophorectomy, hysteroscopic sterilization, and/or tubal ligation, or men who have documented azoospermia) are eligible without requiring the use o
排除标准
- •1. Pregnant or breastfeeding or planning to become pregnant during the study period
- •2. Known allergy to Rencofilstat, cyclosporine, or any of their inactive ingredients
- •3. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb). If HCVAb test is positive, then an HCVRNA test will be performed. If this test is negative, the subject is allowed to participate in the study, as long as the subject meets all other inclusion criteria and has never been treated for HCV or was treated >2 years ago and achieved a sustained virologic response at that time
- •4. Subjects with suspected and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection identified prior to first dose
- •5. History of or any current medical condition which could compromise the safety of the participant in the study, as determined by the investigator
- •6. Clinically significant gastrointestinal, cardiovascular, neurologic, psychiatric, renal, hepatic, respiratory, inflammatory, or infectious disease, as determined by the investigator
- •7. Subjects with a history of clinically significant acute cardiac events within 30 days prior to Screening such as stroke, transient ischemic attack, or coronary heart disease
- •8. Subjects with uncontrolled or unstable cardiac arrhythmias:
- •a. Severe conduction disturbance (e.g., second-degree or third-degree AV block)
- •b. History of congenital long QT syndrome, congenital short QT syndrome, Torsades de Pointes, or Wolff Parkinson White syndrome
- •9. Safety laboratory abnormalities at Screening which are clinically significant as determined by the investigator
- •10. transaminases >5 x upper limit of normal (ULN)
- •11. ALP >2 x ULN
- •12. total serum bilirubin >1.5 x ULN
- •13. platelet count <100,000/mm3
- •14. INR = 1.3 in the absence of anticoagulants.
- •15. albumin <3.5 g/dL.
- •16. Model for End-Stage Liver Disease (MELD) score >12, unless due to an alternate etiology such as therapeutic anticoagulation
- •17. Current or previous (within the past 6 months) Child-Pugh (CP) score = 7 for F2 or F3, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation
- •18.(eGFR) <60 mL/min/1.73 m2
- •19. Hemoglobin A1c (HbA1c) >9.5%.
- •20. Use of systemic immunosuppression therapies within 6 months prior to the first dose of study drug apart from short-term treatment for asthma, inclusive of agents targeting arthritic conditions or chronic skin conditions
- •21. Current clinically significant diarrhea or gastric stasis that in the investigator’s opinion could influence drug absorption or bioavailability
- •22. any history or presence of decompensated cirrhosis including ascites, hepatic encephalopathy or variceal bleeding
- •23. Other well documented causes of chronic liver disease according to standard diagnostic procedures including, but not restricted to:
- •a. Suspicion of drug-induced liver disease.
- •b. Alcoholic liver disease.
- •c. Autoimmune hepatitis.
- •d. Wilson’s disease.
- •e. Primary biliary cholangitis, primary sclerosing cholangitis.
- •f. Genetic hemochromatosis (Homozygosity for C282Y or C282Y/H63D compound heterozygote).
- •g. Known or suspected hepatocellular carcinoma (HCC).
- •h. History or planned liver transplant.
- •i. Clinical evidence of portal hypertension such as esophageal varices, ascites, history of hepatic encephalopathy, or splenomegaly.
- •24. History of hepatic decompensating events or subjects who develop manifestations of hepatic decompensatio
研究者
相似试验
进行中（未招募）
1 期
ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSISONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSISEUCTR2021-005185-18-ITHepion Pharmaceuticals, Inc336
进行中（未招募）
1 期
ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSISEUCTR2021-005185-18-HUHepion Pharmaceuticals, Inc.336
进行中（未招募）
不适用
A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION WITH RIBAVIRIN IN INTERFERON ALFA NAIVE SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1Hepatitis type C chronicEUCTR2005-000867-24-DEHuman Genome Sciences, Inc.460
进行中（未招募）
不适用
A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION WITH RIBAVIRIN IN INTERFERON ALFA NAIVE SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1Chronic hepatitis CMedDRA version: 8.0Level: LLTClassification code 10008912EUCTR2005-000867-24-CZHuman Genome Sciences, Inc.460
招募中
不适用
A MULTI-CENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY FOLLOWED BY AN EXTENSION PERIOD EVALUATING THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUSSystemic lupus erythematosusPER-044-16CB Biopharma SPRL,26